<SEC-DOCUMENT>0001558370-24-010223.txt : 20240726
<SEC-HEADER>0001558370-24-010223.hdr.sgml : 20240726
<ACCEPTANCE-DATETIME>20240726085025
ACCESSION NUMBER:		0001558370-24-010223
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20240726
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240726
DATE AS OF CHANGE:		20240726

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ProMIS Neurosciences Inc.
		CENTRAL INDEX KEY:			0001374339
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			Z4
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41429
		FILM NUMBER:		241143669

	BUSINESS ADDRESS:	
		STREET 1:		SUITE 200, 1920 YONGE STREET
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M4S 3E2
		BUSINESS PHONE:		416-847-6898

	MAIL ADDRESS:	
		STREET 1:		SUITE 200, 1920 YONGE STREET
		CITY:			TORONTO
		STATE:			A6
		ZIP:			M4S 3E2

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMORFIX LIFE SCIENCES LTD
		DATE OF NAME CHANGE:	20060831
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>pmn-20240726x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.7.0.1 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 7/26/2024 12:31:51 PM -->
<!-- iXBRL Library version: 1.0.8923.15446 -->
<!-- iXBRL Service Job ID: c18aebff-b4ee-44c3-afc9-714d7112f55b -->
<html xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:pmn="http://promisneurosciences.com/20240726" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html"/><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_7_26_2024_To_7_26_2024_jaEyxGl83kyP1gSrWS6X0w" name="dei:EntityCentralIndexKey" id="Tc_6KjXJbq_Dkq1xCna4Oy1OA_2_1">0001374339</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_26_2024_To_7_26_2024_jaEyxGl83kyP1gSrWS6X0w" name="dei:AmendmentFlag" id="Tc_W4VG8BA-kEG4rd_vAQC6MA_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="pmn-20240726.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="Duration_7_26_2024_To_7_26_2024_jaEyxGl83kyP1gSrWS6X0w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001374339</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-26</xbrli:startDate><xbrli:endDate>2024-07-26</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;text-indent:0pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_e77b90c7_0971_4e54_8ac6_f306e87b79dc"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:18pt;text-align:center;text-indent:0pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_7_26_2024_To_7_26_2024_jaEyxGl83kyP1gSrWS6X0w" name="dei:DocumentType" id="Narr_clIYWxzf00q_-g3DuxV_ZA"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Pursuant to Section&#160;13 or 15(d)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">of the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Date of Report (Date of earliest event reported): </b><ix:nonNumeric contextRef="Duration_7_26_2024_To_7_26_2024_jaEyxGl83kyP1gSrWS6X0w" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_t8MXzaApHkWA-RLPyTmDSw"><b style="font-weight:bold;">July 26, 2024</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:24pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_26_2024_To_7_26_2024_jaEyxGl83kyP1gSrWS6X0w" name="dei:EntityRegistrantName" id="Narr_2Ol5suuf60S8BHApZml9zw"><b style="font-weight:bold;">PROMIS NEUROSCIENCES&#160;INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Exact name of registrant as specified in its charter)</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:100%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_e55439ec_4149_45bb_94a7_b731a68919b0"></a><a id="Tc_iK1G7jCzRE6REZBTYpVvQw_1_0"></a><a id="Tc_gPNjzPS7kUeiteRhehAzQw_1_2"></a><a id="Tc_ARazcbPCfEuLpzZhJmuprg_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:33.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_26_2024_To_7_26_2024_jaEyxGl83kyP1gSrWS6X0w" format="ixt-sec:edgarprovcountryen" name="dei:EntityIncorporationStateCountryCode" id="Tc_XaKXzy2nI0WD6uW53xTY8A_0_0"><b style="font-weight:bold;">Canada</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:31.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_26_2024_To_7_26_2024_jaEyxGl83kyP1gSrWS6X0w" name="dei:EntityFileNumber" id="Tc_OVjiROnb_kGq0CUq95lKXg_0_2"><b style="font-weight:bold;">001-41429</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:31.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_26_2024_To_7_26_2024_jaEyxGl83kyP1gSrWS6X0w" name="dei:EntityTaxIdentificationNumber" id="Tc_bjoZFl9DV0yxnLJA9DUvlQ_0_4"><b style="font-weight:bold;">98-0647155</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:33.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(State or other jurisdiction</b><br/><b style="font-weight:bold;">of incorporation)</b></p></td><td style="vertical-align:top;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Commission</b><br/><b style="font-weight:bold;">File Number)</b></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(IRS Employer</b><br/><b style="font-weight:bold;">Identification No.)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_a9c8a93d_1b94_4d35_b5da_4b20628eb38d"></a><a id="Tc_tc3sVKTwbEG86RD5KilfNw_1_0"></a><a id="Tc_dXdxa_ROvkGmctUpNW_Pjw_2_0"></a><a id="Tc_P6SzLmcGaE29SVjPOw3qDw_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:31.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:31.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:33.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_26_2024_To_7_26_2024_jaEyxGl83kyP1gSrWS6X0w" name="dei:EntityAddressAddressLine1" id="Narr_pCQMugIMJEOCnxJwHkeOhg"><b style="font-weight:bold;">Suite&#160;200</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_7_26_2024_To_7_26_2024_jaEyxGl83kyP1gSrWS6X0w" name="dei:EntityAddressAddressLine2" id="Narr_fMPtD7OoIku2o4Gqjue2yQ"><b style="font-weight:bold;">1920 Yonge Street</b></ix:nonNumeric><b style="font-weight:bold;">, </b><br/><ix:nonNumeric contextRef="Duration_7_26_2024_To_7_26_2024_jaEyxGl83kyP1gSrWS6X0w" name="dei:EntityAddressCityOrTown" id="Narr_NHZOZqGZtkOoZAZc0q8Log"><b style="font-weight:bold;">Toronto</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_7_26_2024_To_7_26_2024_jaEyxGl83kyP1gSrWS6X0w" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince" id="Narr_hif9EP38bEe53-ar13OHUg"><b style="font-weight:bold;">Ontario</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:31.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:31.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_26_2024_To_7_26_2024_jaEyxGl83kyP1gSrWS6X0w" name="dei:EntityAddressPostalZipCode" id="Tc_D0Dva5gvlkO8TEYF5wdVsA_1_4"><b style="font-weight:bold;">M4S 3E2</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:33.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Address of principal executive</b><br/><b style="font-weight:bold;">offices)</b></p></td><td style="vertical-align:bottom;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:31.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:31.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">(Zip Code)</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Registrant&#8217;s telephone number, including area code: (</b><ix:nonNumeric contextRef="Duration_7_26_2024_To_7_26_2024_jaEyxGl83kyP1gSrWS6X0w" name="dei:CityAreaCode" id="Narr_sVctCh4rlUy9U00FX4gtTg"><b style="font-weight:bold;">416</b></ix:nonNumeric><b style="font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_7_26_2024_To_7_26_2024_jaEyxGl83kyP1gSrWS6X0w" name="dei:LocalPhoneNumber" id="Narr_HpgGiSE1P0m7wfNXtpn5Gg"><b style="font-weight:bold;">847-6898</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 8pt 0pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 8pt 0pt;"><ix:nonNumeric contextRef="Duration_7_26_2024_To_7_26_2024_jaEyxGl83kyP1gSrWS6X0w" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_wqju7cr8LEW49HAeS5IfuQ"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 8pt 0pt;"><ix:nonNumeric contextRef="Duration_7_26_2024_To_7_26_2024_jaEyxGl83kyP1gSrWS6X0w" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_azGtILZO-Ua7mlCDiLx7gg"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160; Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 8pt 0pt;"><ix:nonNumeric contextRef="Duration_7_26_2024_To_7_26_2024_jaEyxGl83kyP1gSrWS6X0w" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_kx8qZtowMEuluI7UvRT-FQ"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 8pt 0pt;"><ix:nonNumeric contextRef="Duration_7_26_2024_To_7_26_2024_jaEyxGl83kyP1gSrWS6X0w" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_KEh9GC8U9ESnFh_rmgojKg"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric>&#160;&#160;Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 8pt 0pt;"><b style="font-weight:bold;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</b></p><a id="_74d67a36_7a0d_41c9_8325_4889e2447f26"></a><a id="Tc_jxrz-djBrkubhdmrJ_DrsA_1_0"></a><a id="Tc_7BfUiEVNZU-X2OIaC5zsgw_1_2"></a><a id="Tc_q4N3lkPHGk-v2lZ3IGHgiQ_1_4"></a><a id="Tc_uobPqZzJgkWH6Gz06fJ43g_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:34.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:17.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:34.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Title of Each Class</b></p></td><td style="vertical-align:bottom;width:2.2%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:17.59%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:bottom;width:2.2%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:43%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Name of Each Exchange on Which Registered</b></p></td></tr><tr><td style="vertical-align:middle;width:34.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_26_2024_To_7_26_2024_jaEyxGl83kyP1gSrWS6X0w" name="dei:Security12bTitle" id="Tc_tQTy7tIjW0ed6w56vMbKGg_2_0">Common Shares, no par value per share</ix:nonNumeric></p></td><td style="vertical-align:middle;width:2.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:17.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_26_2024_To_7_26_2024_jaEyxGl83kyP1gSrWS6X0w" name="dei:TradingSymbol" id="Tc_iMgUnNkhkk2cjj31r5j_mg_2_2">PMN</ix:nonNumeric></p></td><td style="vertical-align:middle;width:2.2%;margin:0pt;padding:0pt;"/><td style="vertical-align:middle;width:43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">The <ix:nonNumeric contextRef="Duration_7_26_2024_To_7_26_2024_jaEyxGl83kyP1gSrWS6X0w" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Narr_SV1Yecb5nUaYuV7BYiWHSQ">Nasdaq</ix:nonNumeric> Capital Market</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 8pt 0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;text-indent:18pt;margin:0pt 0pt 8pt 0pt;">Emerging growth company&#160;&#160;<ix:nonNumeric contextRef="Duration_7_26_2024_To_7_26_2024_jaEyxGl83kyP1gSrWS6X0w" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_-gMqFU3YiUWxh-nHE-YPUQ"><span style="font-family:'Segoe UI Symbol';">&#9746;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 8pt 0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <ix:nonNumeric contextRef="Duration_7_26_2024_To_7_26_2024_jaEyxGl83kyP1gSrWS6X0w" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="Narr_94j0zeG9p0Kr8vp-VmWx7w"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:justify;text-indent:0pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Item 7.01 Regulation FD Disclosure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On July 26, 2024, ProMIS Neurosciences Inc. (the &#8220;Company&#8221;) issued a press release announcing positive data from the first four cohorts in its first-in-human Phase 1a clinical trial of PMN310 in healthy volunteers (&#8220;Press Release&#8221;). A copy of the Press Release is attached hereto as Exhibit 99.1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item 8.01 Other Events.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">On July 26, 2024, the Company issued the Press Release announcing positive data from the first four cohorts in its first-in-human Phase 1a clinical trial of PMN310 in healthy volunteers. PMN310 was generally well-tolerated through the first four single-ascending (SAD) dose cohorts (2.5, 5, 10, 20 mg/kg), with no treatment-emergent serious adverse events (SAEs) observed after administration of PMN310. Cerebrospinal fluid (CSF) collection was done on days 3 and 29 after PMN310 administration. Measurement of PMN310 levels in CSF showed dose proportionality at both days 3 and 29, with the lowest dose reaching a greater than 100-fold molar excess compared to expected levels of oligomers in the CSF. The half-life of PMN310 in CSF was approximately 25 days, which is supportive of once per month dosing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">The Phase 1a clinical trial was a randomized, double-blind, placebo-controlled study evaluating the safety and tolerability of PMN310 in healthy  volunteers (NCT06105528). The study consisted of five SAD cohorts and was designed to evaluate the safety, tolerability, and pharmacokinetics (PK), of intravenous doses of PMN310. The study completed enrollment of all 40 subjects across 2 active sites in the United States. The Company has completed its analysis of the first four cohorts with the fifth and final cohort undergoing final analysis; we anticipate the fifth cohort will yield similar encouraging results. The trial was initiated based on encouraging nonclinical studies of PMN310 that support the selective targeting of A&#946;Os.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">The Company expects to present the full dataset at an upcoming medical meeting in the second half of 2024. The Company plans to advance PMN310 into the Phase 1b portion of the clinical study in the coming months.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Forward-Looking Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">This Current Report on Form 8-K contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Certain information in this Current Report on Form 8-K constitutes forward-looking statements and forward-looking information (collectively, &#8206;&#8206;&#8220;forward-looking information&#8221;) within the meaning of applicable securities laws. In some cases, but not necessarily in all cases, forward-looking information can be identified by the &#8206;use of forward-looking terminology such as &#8220;plans&#8221;, &#8220;excited to&#8221;, &#8220;targets&#8221;, &#8220;expects&#8221; or &#8220;does not expect&#8221;, &#8220;is expected&#8221;, &#8220;an opportunity exists&#8221;, &#8206;&#8206;&#8220;is positioned&#8221;, &#8220;estimates&#8221;, &#8220;intends&#8221;, &#8220;assumes&#8221;, &#8220;anticipates&#8221; or &#8220;does not anticipate&#8221; or &#8220;believes&#8221;, or variations of such words and &#8206;phrases or state that certain actions, events or results &#8220;may&#8221;, &#8220;could&#8221;, &#8220;would&#8221;, &#8220;might&#8221;, &#8220;will&#8221; or &#8220;will be taken&#8221;, &#8220;occur&#8221; or &#8220;be &#8206;achieved&#8221;. In addition, any statements that refer to expectations, projections or other characterizations of future events or &#8206;circumstances contain forward-looking information. Specifically, this Current Report on Form 8-K contains forward-looking information relating to the Company&#8217;s top-line results from the first four cohorts of its Phase 1a study and the potential implications thereof, the analysis and expected results of the fifth cohort; the Company's expectations regarding its clinical development of its lead product, PMN310, for AD, and the Company&#8217;s anticipated top-line data readout for all five cohorts of its Phase 1a study in the coming months and plans to advance into a Phase 1b multiple ascending dose study in AD patients in the coming months. Statements containing forward-looking information are not historical facts but instead represent management's current &#8206;expectations, estimates and projections regarding the future of our business, future plans, strategies, projections, anticipated events &#8206;and trends, the economy and other future conditions. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this Current Report on Form 8-K, are subject to &#8206;known and unknown risks, uncertainties and assumptions and other factors that may cause the actual results, level of activity, &#8206;performance or achievements to be materially different from those expressed or implied by such forward-looking information, including, but not limited to, the risk that the results of nonclinical studies and early clinical trials are not necessarily predictive of </p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">future results with PMN310, the Company&#8217;s ability to fund its operations and continue as a going concern, its accumulated deficit and the expectation for continued losses and future financial results. Important factors that could cause actual results to differ materially from those indicated in the forward-looking information include, among others, the factors discussed throughout the &#8220;Risk Factors&#8221; section of the Company's most recently filed Annual Report on Form 10-K for the year ended December 31, 2023 and in its subsequent filings filed with the United States Securities and Exchange Commission. Except as required by applicable securities laws, the Company undertakes no obligation to publicly update any forward-looking information, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Item 9.01 Financial Statements and Exhibits.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">(d)&#160;Exhibits</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:10.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:87.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:10.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;No.</b></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:top;width:87.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Description</b></p></td></tr><tr><td style="vertical-align:top;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="pmn-20240726xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">99.1</span></a></p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:87.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="pmn-20240726xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Press Release, dated July 26, 2024</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">104</p></td><td style="vertical-align:top;width:2.06%;margin:0pt;padding:0pt;"/><td style="vertical-align:top;width:87.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_cbe18623_6a19_414e_944b_7a42f40d41ea"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:48.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:51.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">PROMIS NEUROSCIENCES&#160;INC.</b></p></td></tr><tr><td style="vertical-align:top;width:48.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:48.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: July 26, 2024</p></td><td style="vertical-align:top;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:48.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Neil Warma</p></td></tr><tr><td style="vertical-align:top;width:48.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name: Neil Warma</p></td></tr><tr><td style="vertical-align:top;width:48.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:48.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title: Interim Chief Executive Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>pmn-20240726xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 7/26/2024 12:31:50 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><img src="pmn-20240726xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:42.74pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:125.98pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">ProMIS Neurosciences Reports Promising Top-Line Data from its Phase 1a Alzheimer&#39;s Trial</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><i style="font-size:12pt;font-style:italic;">Topline results demonstrated </i><i style="font-size:12pt;font-style:italic;">a favorable safety profile and</i><i style="font-style:italic;"> </i><i style="font-size:12pt;font-style:italic;">tolerability across four ascending dose levels in healthy volunteers and showed dose dependent levels of PMN310 antibody in Cerebrospinal fluid (CSF) suggestive of its potential for target engagement in Alzheimer&#8217;s disease patients</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">CAMBRIDGE, Massachusetts and TORONTO, Ontario</b><font style="font-size:12pt;">, July 26, 2024 &#8211; ProMIS Neurosciences, Inc. (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer&#8217;s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced positive top-line data from the first four cohorts of its first-in-human Phase 1a clinical trial of PMN310 in healthy volunteers.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">The Phase 1a clinical data, which has been collected and analyzed from the first four of five cohorts, indicated that PMN310 demonstrated a favorable safety profile and was well tolerated and, importantly, crossed the blood brain barrier in healthy volunteers, in a dose dependent manner and at concentrations that suggest sufficient target engagement in the planned follow-on clinical trial in Alzheimer&#8217;s patients.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">&quot;Today&#39;s announcement marks a pivotal moment for ProMIS and the Alzheimer&#39;s community that underscores our progress advancing PMN310 as a potentially transformative therapeutic option for early Alzheimer&#39;s disease,&quot; said Neil Warma, Chief Executive Officer of ProMIS Neurosciences. &quot;These data are a positive first step in evaluating the potential of our antibody therapeutic candidates, which are designed to selectively target toxic misfolded proteins in neurodegenerative diseases. We are looking forward to advancing PMN310 into the Phase 1b portion of the clinical study in Alzheimer&#8217;s patients, which we expect to initiate in the coming months.&quot;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">PMN310 builds on a large body of scientific evidence that points to the role of soluble amyloid-beta oligomers (A</font><font style="font-family:'Symbol';">b</font><font style="font-size:12pt;">O) as a primary driver of Alzheimer&#8217;s pathology. By selectively targeting toxic oligomers, ProMIS seeks to expand therapeutic options beyond those treatments that target amyloid plaques, which it believes could provide a differentiated treatment for AD patients.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">PMN310 Appears Well-Tolerated Across Four Dose Cohorts</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">PMN310 was generally well-tolerated through the first four single-ascending (SAD) dose cohorts (2.5, 5, 10, 20 mg/kg), with no treatment-emergent serious adverse events (SAEs) observed after administration of PMN310. Cerebrospinal fluid (CSF) collection was done on days 3 and 29 after PMN310 administration. Measurement of PMN310 levels in CSF showed dose proportionality at both days 3 and 29, with the lowest dose reaching a greater than 100-fold molar excess compared to expected levels of oligomers in the CSF. The half-life of PMN310 in CSF was approximately 25 days, which is supportive of once per month dosing. </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">&#8220;These encouraging data from the first four cohorts of our first-in-human Phase 1a clinical trial of PMN310 in healthy volunteers support the safety and tolerability profile of PMN310, and the levels of PMN310 in the CSF suggest its potential for target engagement,&#8221; noted Larry Altstiel, M.D., Ph.D., Chief Medical Officer of ProMIS Neurosciences. &#8220;Importantly, these results will inform the dosing of our Phase 1b clinical trial in Alzheimer&#8217;s patients, which is on track to initiate in the second half of 2024.&#8221; </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">The Phase 1a clinical trial was a randomized, double-blind, placebo-controlled study evaluating the safety and tolerability of PMN310 in healthy &#160;volunteers (NCT06105528). The study consisted of five SAD cohorts and was designed to evaluate the safety, tolerability, and pharmacokinetics (PK), of intravenous doses of PMN310. The study completed enrollment of all 40 subjects across 2 active sites in the United States. The company has </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><img src="pmn-20240726xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:42.74pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:125.98pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">completed its analysis of the first four cohorts with the fifth and final cohort undergoing final analysis; we anticipate the fifth cohort will yield similar encouraging results. The trial was initiated based on encouraging nonclinical studies of PMN310 that support the selective targeting of A&#946;Os.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">ProMIS expects to present the full dataset at an upcoming medical meeting in the second half of 2024.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">About PMN310</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">PMN310 is a humanized monoclonal antibody (mAb) designed and developed based on its selectivity for soluble amyloid beta oligomers (A&#946;Os), which ProMIS believes are the most toxic and pathogenic form of A&#946;, relative to A&#946; monomers and amyloid plaques. Soluble A&#946;Os have been observed to be potent neurotoxins that bind to neurons, inhibit synaptic function and induce neurodegeneration. By selectively targeting toxic soluble A&#946;Os, PMN310 aims to directly address what a growing body of evidence indicates is a primary underlying cause of the neurodegenerative process in Alzheimer&#8217;s disease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">For more information on the &#160;Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of the Safety, Tolerability and Pharmacokinetics of PMN310 Infusions in Healthy Volunteers study (NCT06105528), please visit www.clinicaltrials.gov.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">About ProMIS Nurosciences, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">ProMIS Neurosciences Inc. is a clinical stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer&#8217;s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). The Company&#8217;s proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS&#8482; and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. ProMIS has offices in Cambridge, Massachusetts and Toronto, Ontario.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Forward-Looking Statements </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">This press release contains forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Certain information in this news release constitutes forward-looking statements and forward-looking information (collectively, &#8206;&#8206;&#8220;forward-looking information&#8221;) within the meaning of applicable securities laws. In some cases, but not necessarily in all cases, forward-looking information can be identified by the &#8206;use of forward-looking terminology such as &#8220;plans&#8221;, &#8220;excited to&#8221;, &#8220;targets&#8221;, &#8220;expects&#8221; or &#8220;does not expect&#8221;, &#8220;is expected&#8221;, &#8220;an opportunity exists&#8221;, &#8206;&#8206;&#8220;is positioned&#8221;, &#8220;estimates&#8221;, &#8220;intends&#8221;, &#8220;assumes&#8221;, &#8220;anticipates&#8221; or &#8220;does not anticipate&#8221; or &#8220;believes&#8221;, or variations of such words and &#8206;phrases or state that certain actions, events or results &#8220;may&#8221;, &#8220;could&#8221;, &#8220;would&#8221;, &#8220;might&#8221;, &#8220;will&#8221; or &#8220;will be taken&#8221;, &#8220;occur&#8221; or &#8220;be &#8206;achieved&#8221;. In addition, any statements that refer to expectations, projections or other characterizations of future events or &#8206;circumstances contain forward-looking information. Specifically, this news release contains forward-looking information relating to the Company&#8217;s top-line results from the first four cohorts of its Phase 1a study and the potential implications thereof, the analysis and expected results of the fifth cohort; the Company&#39;s expectations regarding its clinical development of its lead product, PMN310, for AD, and the Company&#8217;s anticipated top-line data readout for all five cohorts of its Phase 1a study in the coming months and plans to advance into a Phase 1b multiple ascending dose study in AD patients in the second half of 2024. Statements containing forward-looking information are not historical facts but instead represent management&#39;s current &#8206;expectations, estimates and projections regarding the future of our business, future plans, strategies, projections, anticipated events &#8206;and trends, the economy and other future conditions. Forward-looking </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><img src="pmn-20240726xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:42.74pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:125.98pt;"></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to &#8206;known and unknown risks, uncertainties and assumptions and other factors that may cause the actual results, level of activity, &#8206;performance or achievements to be materially different from those expressed or implied by such forward-looking information, including, but not limited to, the risk that the results of nonclinical studies and early clinical trials are not necessarily predictive of future results with PMN310, the Company&#8217;s ability to fund its operations and continue as a going concern, its accumulated deficit and the expectation for continued losses and future financial results. Important factors that could cause actual results to differ materially from those indicated in the forward-looking information include, among others, the factors discussed throughout the &#8220;Risk Factors&#8221; section of the Company&#39;s most recently filed Annual Report on Form 10-K for the year ended December 31, 2023 and in its subsequent filings filed with the United States Securities and Exchange Commission. Except as required by applicable securities laws, the Company undertakes no obligation to publicly update any forward-looking information, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">For further information:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Visit us at www.promisneurosciences.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Please submit media inquiries to info@promisneurosciences.com.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">For Investor Relations, please contact:</b><font style="font-size:12pt;"><br></font><font style="font-size:12pt;">Precision AQ</font><font style="font-size:12pt;"><br></font><font style="font-size:12pt;">Anne Marie Fields, Managing Director</font><font style="font-size:12pt;"><br></font><font style="font-size:12pt;">annemarie.fields@precisionaq.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:12pt;">Tel. 212-362-1200</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>pmn-20240726xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pmn-20240726xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1"  Y *@# 2(  A$! Q$!_\0
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$4 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>pmn-20240726.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.7.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 7/26/2024 12:31:57 PM-->
<!--Modified on: 7/26/2024 12:31:57 PM-->
<xsd:schema targetNamespace="http://promisneurosciences.com/20240726" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:srt-roles="http://fasb.org/srt-roles/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2023" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:pmn="http://promisneurosciences.com/20240726" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="pmn-20240726_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="pmn-20240726_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="pmn-20240726_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:roleType roleURI="http://promisneurosciences.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>pmn-20240726_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.7.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 7/26/2024 12:31:57 PM-->
<!--Modified on: 7/26/2024 12:31:57 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <link:roleRef roleURI="http://promisneurosciences.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="pmn-20240726.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:definitionLink xlink:role="http://promisneurosciences.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>pmn-20240726_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.7.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 7/26/2024 12:31:57 PM-->
<!--Modified on: 7/26/2024 12:31:57 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Adress Line Two</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address State Or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>pmn-20240726_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.7.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 7/26/2024 12:31:57 PM-->
<!--Modified on: 7/26/2024 12:31:57 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="pmn-20240726.xsd#DocumentDocumentAndEntityInformation" roleURI="http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638575939171208599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_638575939171208599" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638575939171208599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638575939171208599" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638575939171208599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_638575939171208599" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638575939171208599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638575939171208599" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638575939171208599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_638575939171208599" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638575939171208599" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638575939171208599" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638575939171218584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638575939171218584" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638575939171218584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_638575939171218584" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638575939171218584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638575939171218584" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638575939171218584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638575939171218584" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638575939171218584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638575939171218584" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638575939171218584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_638575939171218584" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638575939171218584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_638575939171218584" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_638575939171218584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications_638575939171218584" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_638575939171218584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial_638575939171218584" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_638575939171218584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer_638575939171218584" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_638575939171228584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_638575939171228584" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638575939171228584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_638575939171228584" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638575939171228584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_638575939171228584" order="19" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638575939171228584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_638575939171228584" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638575939171228584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638575939171228584" order="21" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_638575939171228584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod_638575939171228584" order="22" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638575939171228584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638575939171228584" order="23" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638575939171228584" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_638575939171228584" order="24" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2</span><table class="report" border="0" cellspacing="2" id="idm140648299113088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jul. 26, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul. 26,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PROMIS NEUROSCIENCES&#160;INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">Z4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-0647155<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">Suite&#160;200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Adress Line Two</a></td>
<td class="text">1920 Yonge Street<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Toronto<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address State Or Province</a></td>
<td class="text">ON<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">M4S 3E2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">416<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">847-6898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Shares, no par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PMN<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001374339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M[M +KF$%EROBN#\M?R8^"S*HMWWMSA97,O4)RZV_H6 P-T1(DE!%WFB4,9+
M6%-S 6.N_-^]8-B*AJ;V_'V\E+65=T%@_H)YJGORHH!;\S%:9+P+-M2L<N?V
MDQ>$ID/_:?@[QE3YO'N5SX]CIM8F2.] 06^,>R14U.<5%]0J0]-6>;R+6_21
M;$<@@?"2G>_.BI>$6BQ<[>(4J"S?O>JM8 334X'W3V!F[LA[5A\K7,J&+6VS
M[36;V);6K:S?Q1U[")81YK;Q'-%U+<]W6G[CY/W=? MYH:9:4A*Q%0C9=VT8
MIRH^+Q0-+9/\E7XIM99Q?KAA%#S,W #75U+J8\-\)2@_\@S^!5!+ P04
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MJ'7N0;#W\!J-'<V/'[?\ 5!+ P04    " !,1OI8)!Z;HJT   #X 0  &@
M 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4 -5"I0P5,
M75@K+A %\R,2$L6N"K<OA0&0.G1ALIXM?^_)3I]H%'=NH+;S)$9K!LIDR^SO
M *1;M(HNSN,P3VH7K.)9A@:\TKUJ$)(HND'8,V2>[IFBG#S^0W1UW6E\./VR
M./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6?;!/
M3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @ 3$;Z6&60>9(9 0  SP,
M !,   !;0V]N=&5N=%]4>7!E<UTN>&ULK9--3L,P$(6O$F5;)2XL6*"F&V +
M77 !8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5
M!TYB'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T<F^I>.EY&TWP
M39G 8ED\C<+,:DH9HS5*$M?%P>L?E.I$J+EST&!G(BY84(JKA%SY'7#J>SM
M2D9#L9&)7J5CE>BM0#I:P'K:XLH90]L:!3JHO>.6&F,"J;$#(&?KT70Q32:>
M,(S/N]G\P68*R,I-"A$YL01_QYTCR=U59"-(9*:O>"&R]>S[04Y;@[Z1S>/]
M#&DWY(%B6.;/^'O&%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4
M" !,1OI8!T%-8H$   "Q    $               @ $     9&]C4')O<',O
M87!P+GAM;%!+ 0(4 Q0    ( $Q&^ECB'@YO[P   "L"   1
M  "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( $Q&^EB97)PC
M$ 8  )PG   3              "  <T!  !X;"]T:&5M92]T:&5M93$N>&UL
M4$L! A0#%     @ 3$;Z6% R#*F)!   \!$  !@              ("!#@@
M 'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( $Q&^EB?H!OP
ML0(  .(,   -              "  <T,  !X;"]S='EL97,N>&UL4$L! A0#
M%     @ 3$;Z6)>*NQS     $P(   L              ( !J0\  %]R96QS
M+RYR96QS4$L! A0#%     @ 3$;Z6!PX9>H_ 0  / (   \
M ( !DA   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( $Q&^E@D'INBK0
M /@!   :              "  ?X1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<U!+ 0(4 Q0    ( $Q&^EAED'F2&0$  ,\#   3              "
M >,2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  "T4
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="pmn-20240726x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>pmn-20240726.xsd</File>
    <File>pmn-20240726_def.xml</File>
    <File>pmn-20240726_lab.xml</File>
    <File>pmn-20240726_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="pmn-20240726x8k.htm">pmn-20240726x8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "pmn-20240726x8k.htm": {
   "nsprefix": "pmn",
   "nsuri": "http://promisneurosciences.com/20240726",
   "dts": {
    "schema": {
     "local": [
      "pmn-20240726.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "definitionLink": {
     "local": [
      "pmn-20240726_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "pmn-20240726_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pmn-20240726_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "pmn-20240726x8k.htm"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 24
   },
   "report": {
    "R1": {
     "role": "http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "Duration_7_26_2024_To_7_26_2024_jaEyxGl83kyP1gSrWS6X0w",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20240726x8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_26_2024_To_7_26_2024_jaEyxGl83kyP1gSrWS6X0w",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "pmn-20240726x8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Adress Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address State Or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://promisneurosciences.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001558370-24-010223-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-24-010223-xbrl.zip
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MUV%=KZ=(YJ+=90P-*?=D3CI"9ED56MUP=A^+&P3<Q]GN[ ;.['K7H=M0:9%
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M!EGM$7KU_/EDB_4L'\L P2E<B=$RV[#S?AAV"TJ[]/G+WO!R8)?OUM&RV6J
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M#PR;=Y!S=" "D+@@QP=/I3G:A&0$<0?Q0_T*'H?1!-YG6Y3SPA*0!'T*+D>
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MM^1Z6E?4F'7&EP7*GA^O[\H!V%$/L4G,IZ-AT'<]7$&<?@7UHP<Y7:V4+KW
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M2.UTP9H!!:J5#K?"7<NJ5+'U2D0:7NH[%0L Y112P*"PN5*JG-4]IS4F,DP
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M,C R-# W,C8N>'-D4$L! A0#%     @ 3$;Z6.C[Y_GR @  .0L  !0
M         ( !$00  '!M;BTR,#(T,#<R-E]D968N>&UL4$L! A0#%     @
M3$;Z6$9+%E+R!0  ]$4  !0              ( !-0<  '!M;BTR,#(T,#<R
M-E]L86(N>&UL4$L! A0#%     @ 3$;Z6&=C$#NP!   /RX  !0
M     ( !60T  '!M;BTR,#(T,#<R-E]P<F4N>&UL4$L! A0#%     @ 3$;Z
M6 /E0U'O'   8:4  !,              ( !.Q(  '!M;BTR,#(T,#<R-G@X
M:RYH=&U02P$"% ,4    " !,1OI84/6E(@H3  "U3@  %P
M@ %;+P  <&UN+3(P,C0P-S(V>&5X.3ED,2YH=&U02P4&      8 !@"* 0
&FD(

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>pmn-20240726x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="pmn-20240726.xsd" xlink:type="simple"/>
    <context id="Duration_7_26_2024_To_7_26_2024_jaEyxGl83kyP1gSrWS6X0w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001374339</identifier>
        </entity>
        <period>
            <startDate>2024-07-26</startDate>
            <endDate>2024-07-26</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_7_26_2024_To_7_26_2024_jaEyxGl83kyP1gSrWS6X0w"
      id="Tc_6KjXJbq_Dkq1xCna4Oy1OA_2_1">0001374339</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_7_26_2024_To_7_26_2024_jaEyxGl83kyP1gSrWS6X0w"
      id="Tc_W4VG8BA-kEG4rd_vAQC6MA_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_7_26_2024_To_7_26_2024_jaEyxGl83kyP1gSrWS6X0w"
      id="Narr_clIYWxzf00q_-g3DuxV_ZA">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_7_26_2024_To_7_26_2024_jaEyxGl83kyP1gSrWS6X0w"
      id="Narr_t8MXzaApHkWA-RLPyTmDSw">2024-07-26</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_7_26_2024_To_7_26_2024_jaEyxGl83kyP1gSrWS6X0w"
      id="Narr_2Ol5suuf60S8BHApZml9zw">PROMIS NEUROSCIENCES&#160;INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_7_26_2024_To_7_26_2024_jaEyxGl83kyP1gSrWS6X0w"
      id="Tc_XaKXzy2nI0WD6uW53xTY8A_0_0">Z4</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_7_26_2024_To_7_26_2024_jaEyxGl83kyP1gSrWS6X0w"
      id="Tc_OVjiROnb_kGq0CUq95lKXg_0_2">001-41429</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_7_26_2024_To_7_26_2024_jaEyxGl83kyP1gSrWS6X0w"
      id="Tc_bjoZFl9DV0yxnLJA9DUvlQ_0_4">98-0647155</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_7_26_2024_To_7_26_2024_jaEyxGl83kyP1gSrWS6X0w"
      id="Narr_pCQMugIMJEOCnxJwHkeOhg">Suite&#160;200</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="Duration_7_26_2024_To_7_26_2024_jaEyxGl83kyP1gSrWS6X0w"
      id="Narr_fMPtD7OoIku2o4Gqjue2yQ">1920 Yonge Street</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_7_26_2024_To_7_26_2024_jaEyxGl83kyP1gSrWS6X0w"
      id="Narr_NHZOZqGZtkOoZAZc0q8Log">Toronto</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_7_26_2024_To_7_26_2024_jaEyxGl83kyP1gSrWS6X0w"
      id="Narr_hif9EP38bEe53-ar13OHUg">ON</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_7_26_2024_To_7_26_2024_jaEyxGl83kyP1gSrWS6X0w"
      id="Tc_D0Dva5gvlkO8TEYF5wdVsA_1_4">M4S 3E2</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_7_26_2024_To_7_26_2024_jaEyxGl83kyP1gSrWS6X0w"
      id="Narr_sVctCh4rlUy9U00FX4gtTg">416</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_7_26_2024_To_7_26_2024_jaEyxGl83kyP1gSrWS6X0w"
      id="Narr_HpgGiSE1P0m7wfNXtpn5Gg">847-6898</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_7_26_2024_To_7_26_2024_jaEyxGl83kyP1gSrWS6X0w"
      id="Narr_wqju7cr8LEW49HAeS5IfuQ">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_7_26_2024_To_7_26_2024_jaEyxGl83kyP1gSrWS6X0w"
      id="Narr_azGtILZO-Ua7mlCDiLx7gg">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_7_26_2024_To_7_26_2024_jaEyxGl83kyP1gSrWS6X0w"
      id="Narr_kx8qZtowMEuluI7UvRT-FQ">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_7_26_2024_To_7_26_2024_jaEyxGl83kyP1gSrWS6X0w"
      id="Narr_KEh9GC8U9ESnFh_rmgojKg">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_7_26_2024_To_7_26_2024_jaEyxGl83kyP1gSrWS6X0w"
      id="Tc_tQTy7tIjW0ed6w56vMbKGg_2_0">Common Shares, no par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_7_26_2024_To_7_26_2024_jaEyxGl83kyP1gSrWS6X0w"
      id="Tc_iMgUnNkhkk2cjj31r5j_mg_2_2">PMN</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_7_26_2024_To_7_26_2024_jaEyxGl83kyP1gSrWS6X0w"
      id="Narr_SV1Yecb5nUaYuV7BYiWHSQ">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_7_26_2024_To_7_26_2024_jaEyxGl83kyP1gSrWS6X0w"
      id="Narr_-gMqFU3YiUWxh-nHE-YPUQ">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="Duration_7_26_2024_To_7_26_2024_jaEyxGl83kyP1gSrWS6X0w"
      id="Narr_94j0zeG9p0Kr8vp-VmWx7w">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
